Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,505
- 试验地点
- 1
- 主要终点
- Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium
研究概览
简要总结
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age≥75 years old;
- •Treated with PCI (limited to stent implantation) ;
- •Survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at discharge;
排除标准
- •Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization;
- •Concurrent use of oral anticoagulants;
- •Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency;
- •Acute infectious diseases;
- •Cognitive impairment;
- •Declined re-examination.
研究组 & 干预措施
The Elderly Undergoing Percutaneous Coronary Intervention
Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
干预措施: Ticagrelor (Drug)
结局指标
主要结局
Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium
时间窗: 12 months
The primary safety endpoint
Combined major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause mortality, myocardial infarction, ischemic stroke, and any revascularization.
时间窗: 12 months
The primary efficacy endpoint
次要结局
- Incidence of major and minor bleeding defined by the TIMI study(12 months)
- Revascularization(12 months)
- Ischemic stroke(12 months)
- Incidence of BARC3 and 5 bleeding(12 months)
- Incidence of major and minor bleeding defined by the PLATO study(12 months)
- All-cause mortality(12 months)
- Myocardial infarction(12 months)
- Occurrence of any bleeding(12 months)
研究者
Meng Shaoke
M.D.
The First Affiliated Hospital of Dalian Medical University